Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Launch of the nationwide telemedicine solution for COPD in Denmark

24 Nov 2023

In November 2023, the Danish Regions announced the launch of a national telemedicine solution for patients with severe chronic obstructive pulmonary disease (COPD). This is based on previous economic agreements between the government, Danish Regions, and municipalities (KL). 

Regions and municipalities have developed the telemedicine platform Telma in collaboration with Joint Support for Telemedicine (Fælles Understøttellse af Telemedicin, FUT) – an organization that manages the joint telemedicine infrastructure on behalf of the country's municipalities and regions.

The general practitioner or the hospital doctor must refer patients to participate in telemedicine follow-up. The patient is given a tablet and devices that continuously measure, for example, pulse and oxygen in the blood. The nurse from the municipality or hospital reviews and assesses the results. If there are signs of worsening COPD or something else, the nurse contacts the patient to investigate whether further treatment is needed. 

The solution is expected to be fully rolled out during 2024. 

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription service Market Access Monitor every week from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.